Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Dec 21, 2020 6:55pm
160 Views
Post# 32158072

RE:RE:Captured losses 12/3 at 2.35, beat the crowd

RE:RE:Captured losses 12/3 at 2.35, beat the crowdThe issue is lack of demand thus low volume and too small for institutional investors so the company needs to address the real problem which is how to convince the market specifically the retail segment  re the promising future prospects this company can offer as an investment in the medium to long term. This is the part they haven't managed to do so far.
The execution has been too slow, the communication not transparent enough and pass track record mixed IMO as a result no meaningful interest in the stock.
They can fix it but they have to make proper efforts  for instance since the announcement of general NASH now more than three months later have they filed the protocol? They think submission is not material event well in the absence of any other progress any event for this company is material also as mentioned before the program has validity issues and one can interpret not announcing the submission as those issues are more complicated than what we originally guessed.
Point is again they can't  force folks to buy the stocks they need to convince them by making right strategical decisions and that is not illegal so nobody end up being accused of criminal activities. 

Bucknelly21 wrote: I will say I respect rusty I believe he is a great fund manager and very smart, I would disagree with the cap size being a big problem for volume, I was going through a lot of small cap bio stocks that do over a million shares in volume a day with a smaller cap that Thtx. I don't believe that is the issue. 


<< Previous
Bullboard Posts
Next >>